Compare MOH & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOH | KYMR |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 10.6B |
| IPO Year | 2002 | 2020 |
| Metric | MOH | KYMR |
|---|---|---|
| Price | $203.54 | $117.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 26 |
| Target Price | ★ $167.00 | $107.72 |
| AVG Volume (30 Days) | 481.7K | ★ 649.1K |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $45,426,000,000.00 | $39,211,000.00 |
| Revenue This Year | $2.40 | $10.61 |
| Revenue Next Year | $5.18 | $8.17 |
| P/E Ratio | $136.14 | ★ N/A |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $121.06 | $40.10 |
| 52 Week High | $244.89 | $130.05 |
| Indicator | MOH | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 53.03 |
| Support Level | $188.66 | $108.87 |
| Resistance Level | $202.83 | $120.37 |
| Average True Range (ATR) | 6.18 | 4.70 |
| MACD | 0.41 | -0.53 |
| Stochastic Oscillator | 23.51 | 44.61 |
Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.